The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Association of Changes in A1C Following Continuous Glucose Monitoring Acquisition in People with Sub-Optimally Treated Type 2 Diabetes Taking GLP-1 RA Therapy
Open accessAbstract
INTRODUCTION: Both glucagon-like peptide-1 receptor agonists (GLP-1 RA) and continuous glucose monitoring (CGM) improve glycemia in patients with type 2 diabetes (T2D). However, it is unknown whether adding CGM to GLP-1 RA therapy further improves A1c. We evaluated changes in A1c levels 6 months after initiation of FreeStyle Libre (FSL) in adults with sub-optimally controlled T2D already on GLP-1 RA therapy. METHODS: This retrospective, observational study used Optum's de-identified Market Clarity Data, a linked electronic health record-claims database to assess changes in A1c after FSL acquisition. Inclusion criteria were T2D diagnosis, ≥ 18 years, baseline A1c ≥ 8%, with the first FSL acquisition between 2018 and 2022. Patients were required to be on GLP-1 RA prior to FSL with at least one GLP-1 RA prescription within 90 days of FSL acquisition. GLP-1 RA initiation was defined as the earliest GLP-1 RA prescription from 2017 onwards. Paired changes in A1c were assessed at 6 months after initial FSL acquisition. RESULTS: The study cohort included 1454 adults with T2D (age 55 ± 10 years, 52% male, 38% with intensive insulin therapy, median 471 days from GLP-1 RA initiation to FSL, and baseline A1c 9.8 ± 1.5%). After FSL acquisition, patients experienced an A1c decrease of 1.5 ± 1.9% (p < 0.001). Patients with a baseline A1c > 10% had the largest reduction (n = 497, - 2.7 ± 2.2%, p < 0.001). Significant improvements were observed in subgroups based on insulin therapy and GLP-1 RA formulation. Those initiating GLP-1 RA therapy > 24 months before FSL acquisition also showed improvements in A1c (n = 478; - 1.3 ± 1.7%, p < 0.001). CONCLUSIONS: In a large, real-world study of adults with T2D, those on prior GLP-1 RA therapy experienced significant A1c improvements after acquiring FSL, irrespective of GLP-1 RA duration, GLP-1 RA formulation, or insulin therapy type. These findings support the use of FSL in adults with T2D treated with GLP-1 RA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In a cohort of 1454 GLP‐1RA users (30% non‐insulin using), Miller et al. observed a 1.5 ± 1.9% (p < 0.001) HbA1c reduction after acquisition of FSL, which was similar to the 1.7 ± 1.9% reduction seen among just the noninsulin users (n = 432).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bolinder, J., Antuna, R., Geelhoed-Duijvestijn, P., Kröger, J., & Weitgasser, R. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31535-5 · Cited by 893
Lind, M., Polonsky, W., Hirsch, I. B., Heise, T., Bolinder, J., Dahlqvist, S., Schwarz, E., Ólafsdóttir, A. F., Frid, A., Wedel, H., et al. (2017) · JAMA · doi:10.1001/jama.2016.19976 · Cited by 705
Trends in diabetes treatment and control in U.S. adults, 1999-2018
Fang, M., Wang, D., Coresh, J., & Selvin, E. (2021) · New England Journal of Medicine · doi:10.1056/nejmsa2032271 · Cited by 690 · cited 1×
“%) fell from 57.4% in 2007–2010 to 50.5% in 2015–2018 [3].”
Influential9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s009 · Cited by 662 · cited 1×
“The American Diabetes Association’s Standards of Medical Care in Diabetes—2024 recommend prescribing GLP-1 RA to reach appropriate glycemic targets in people with T2D [4].”
BackgroundBeck, R. W., Riddlesworth, T. D., Ruedy, K., Ahmann, A., Haller, S., Kruger, D., McGill, J. B., Polonsky, W., Price, D., Aronoff, S., et al. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2855 · Cited by 635
Heinemann, L., Freckmann, G., Ehrmann, D., Faber-Heinemann, G., Guerra, S., Waldenmaier, D., & Hermanns, N. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30297-6 · Cited by 522
6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s006 · Cited by 486 · cited 2×
“For these people, assessing glycemic status using either blood glucose monitoring (BGM) or continuous glucose monitoring (CGM) in addition to regular A1c testing helps to achieve glycemic goals [1].”
Backgroundvan Beers, C. A. J., DeVries, J. H., Kleijer, S. J., Smits, M. M., Geelhoed-Duijvestijn, P. H., Kramer, M. H. H., Diamant, M., Snoek, F. J., & Serné, E. H. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30193-0 · Cited by 386
Aleppo, G., Ruedy, K. J., Riddlesworth, T. D., Kruger, D. F., Peters, A. L., Hirsch, I., Bergenstal, R. M., Toschi, E., Ahmann, A. J., Shah, V. N., et al. (2017) · Diabetes Care · doi:10.2337/dc16-2482 · Cited by 329
Shi, Q., Nong, K., Vandvik, P. O., Guyatt, G. H., Schnell, O., Rydén, L., Marx, N., Brosius, F. C., Mustafa, R. A., Agarwal, A., et al. (2023) · BMJ · doi:10.1136/bmj-2022-074068 · Cited by 293
7. Diabetes Technology: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s007 · Cited by 281 · cited 1×
“The current American Diabetes Association Stand-ards of Care in Diabetes recommends its use for all insulin users or those at risk for hypo-glycemia [12].”
BackgroundCharleer, S., De Block, C., Van Huffel, L., Broos, B., Fieuws, S., Nobels, F., Mathieu, C., & Gillard, P. (2020) · Diabetes Care · doi:10.2337/dc19-1610 · Cited by 261
Ruedy, K. J., Parkin, C. G., Riddlesworth, T. D., & Graham, C. (2017) · Journal of Diabetes Science and Technology · doi:10.1177/1932296817704445 · Cited by 225
GLP-1 receptor agonist discontinuation among patients with obesity and/or type 2 diabetes
Do, D., Lee, T., Peasah, S. K., Good, C. B., Inneh, A., & Patel, U. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.13172 · Cited by 218 · cited 1×
“However, despite having proven benefits, GLP-1 RA remain underused mostly due to intolerance to side effects or limited efficacy in GLP-1 RA in maintaining optimal glucose control due to the progressive nature of T2D [7, 10, 11].”
BackgroundYaron, M., Roitman, E., Aharon-Hananel, G., Landau, Z., Ganz, T., Yanuv, I., Rozenberg, A., Karp, M., Ish-Shalom, M., Singer, J., et al. (2019) · Diabetes Care · doi:10.2337/dc18-0166 · Cited by 211 · cited 1×
“This finding is consistent with the existing body of evidence, which suggests that the use of CGM results in improved overall glycemic control in individuals treated with intensive insulin, less-intensive insulin, and non-insulin therapies [25, 27, 28, 34, 35].”
ResultTirzepatide, a new era of dual-targeted treatment for diabetes and obesity: A mini-review
Chavda, V. P., Ajabiya, J., Teli, D., Bojarska, J., & Apostolopoulos, V. (2022) · Molecules · doi:10.3390/molecules27134315 · Cited by 208
Haak, T., Hanaire, H., Ajjan, R., Hermanns, N., Riveline, J.-P., & Rayman, G. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0255-6 · Cited by 188
Intermittently scanned continuous glucose monitoring for type 1 diabetes
Leelarathna, L., Evans, M. L., Neupane, S., Rayman, G., Lumley, S., Cranston, I., Narendran, P., Barnard-Kelly, K., Sutton, C. J., Elliott, R. A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2205650 · Cited by 174
Fokkert, M., van Dijk, P., Edens, M., Barents, E., Mollema, J., Slingerland, R., Gans, R., & Bilo, H. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000809 · Cited by 163 · cited 2×
“However, other studies have demonstrated sensor data-driven behavioral changes in both patients and clinicians [16, 36].”
BackgroundOskarsson, P., Antuna, R., Geelhoed-Duijvestijn, P., Krӧger, J., Weitgasser, R., & Bolinder, J. (2018) · Diabetologia · doi:10.1007/s00125-017-4527-5 · Cited by 160
Wada, E., Onoue, T., Kobayashi, T., Handa, T., Hayase, A., Ito, M., Furukawa, M., Okuji, T., Okada, N., Iwama, S., et al. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-001115 · Cited by 157 · cited 2×
“For example, in a randomized controlled study, Wada et al. showed that measuring glucose levels with flash glucose monitoring, such as FSL, resulted in significantly reduced A1c levels by 0.43% in patients with T2D treated with non-insulin ( n = 48) after 12 weeks of use [27].”
BackgroundResultInfluentialWeiss, T., Yang, L., Carr, R. D., Pal, S., Sawhney, B., Boggs, R., Rajpathak, S., & Iglay, K. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002517 · Cited by 152
Aronson, R., Brown, R. E., Chu, L., Bajaj, H. S., Khandwala, H., Abitbol, A., Malakieh, N., & Goldenberg, R. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14949 · Cited by 118 · cited 1×
“Multiple studies have demonstrated benefits of CGM use in people with T2D using insulin [25, 26, 30, 33].”
BackgroundWright, E. E., Kerr, M. S. D., Reyes, I. J., Nabutovsky, Y., & Miller, E. (2021) · Diabetes Spectrum · doi:10.2337/ds20-0069 · Cited by 115
Self-citationKröger, J., Fasching, P., & Hanaire, H. (2020) · Diabetes Therapy · doi:10.1007/s13300-019-00741-9 · Cited by 90
Carlson, A. L., Daniel, T. D., DeSantis, A., Jabbour, S. A., French, E. K., Kruger, D. F., Miller, E. M., Özer, K., & Elliott, T. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002590 · Cited by 78 · cited 1×
“Multiple studies have demonstrated benefits of CGM use in people with T2D using insulin [25, 26, 30, 33].”
BackgroundSelf-citationEvans, M., Welsh, Z., & Seibold, A. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01253-9 · Cited by 67 · cited 2×
“CI confidence intervals on glycemic control in 25 real-world studies showed that the degree of A1c improvement was predicted by the baseline A1c level, such that subjects with a higher initial A1c had, on average, a greater reduction over the intervention period [33].”
BackgroundSchiavon, M., Visentin, R., Göbel, B., Riz, M., Cobelli, C., Klabunde, T., & Dalla Man, C. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14394 · Cited by 49
Flash CGM associated with event reduction in nonintensive diabetes therapy
(2021) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88780 · Cited by 49
Self-citationThe role of GLP-1 receptor agonists in managing type 2 diabetes
Nachawi, N., Rao, P. P., & Makin, V. (2022) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.89a.21110 · Cited by 45
Jung, H., Tittel, S. R., Schloot, N. C., Heitmann, E., Otto, T., Lebrec, J., Pavel, M., & Lanzinger, S. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15038 · Cited by 25
Wright, E. E., Roberts, G. J., Chuang, J. S., Nabutovsky, Y., Virdi, N., & Miller, E. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0015 · Cited by 22
Self-citationConti, M., Massari, G., Meneghini, E., Pasquino, B., Agosti, B., Chinotti, F., Pintaudi, B., Girelli, A., & Bertuzzi, F. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13030642 · Cited by 21 · cited 1×
“A growing body of evidence suggests that there are also benefits for individuals with T2D treated with less-intensive insulin and non-insulin therapies [25–31].”
BackgroundSHIELDS, S., Norman, G. J., & Ciemins, E. L. (2022) · Diabetes · doi:10.2337/db22-687-p · Cited by 14
HUANG, E., NADA, M., & WRIGHT, E. E. (2022) · Diabetes · doi:10.2337/db22-73-lb · Cited by 1
Self-citation
Cited by
Aronson, R., Abitbol, A., Bajaj, H. S., Cheng, A. Y. Y., Christopoulos, S., Harris, S. B., Jain, A. B., & Goldenberg, R. M. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.70008 · Cited by 33
Wright, E. E., Miller, E. M., Bindal, A., & Poon, Y. (2025) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2025.24253 · Cited by 10
Self-citationNemlekar, P. M., Hannah, K. L., Green, C. R., & Norman, G. J. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70089 · Cited by 4
“Miller et al. described significant A1c improvements among people with suboptimally controlled type 2 diabetes following the addition of CGM to prior GLP-1 RA therapy [25].”
Myśliwiec, M., Czupryniak, L., Gellert, R., Jankowski, P., Mastalerz–Migas, A., Rękas, M., Strojek, K., & Walczak, M. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01769-w · Cited by 4
“A significant observa‑ tion has been that individuals with T2D being treated with GLP‑1 RAs gain significant addi‑ tional glycemic benefit if a CGM system is initi‑ ated alongside GLP‑1 RA therapy or added in [64, 65].”
InfluentialHayek, A. A., Klonoff, D. C., Zahrani, W. M. A., Indarkiri, N. Y., & Dawish, M. A. A. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03495-6 · Cited by 2
Metadata
- Authors
- Miller, E., Chuang, J. S., Roberts, G. J., Nabutovsky, Y., Virdi, N., & Wright, E. E.
- Affiliations
- Abbott (United States) (US)
- Abbott Diabetes Care (United States) (US)
- Corresponding author
- Virdi, Naunihal
- Venue
- Diabetes Therapy
- Published
- 2024-07-15
- Volume
- 15
- Issue
- 9
- Pages
- 2027-2038
- ISSN
- 1869-6953 (ISSN-L)
- 1869-6961
- PMC
- PMC11330431
- OpenAlex
- W4400657312
- Cited by
- 9
- References
- 35
- Citations by year
- 2026: 5 · 2025: 4
- FWCI
- 2.96
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- Diabetes Therapy (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Abbott Diabetes Care
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- type 2 diabetes, continuous glucose monitoring, FreeStyle Libre, GLP-1 receptor agonists, HbA1c, HbA1c reduction, glycemic control, insulin therapy, real-world evidence, treatment initiation timing, intensive insulin therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.